In a regulatory filing, KalVista Pharmaceuticals CFO and CBO Benjamin Palleiko disclosed the sale of 40,855 common shares of the company on February 14 at a price of $15.0093 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KALV: